Cargando…

Drug-drug interactions between antithrombotics and direct-acting antivirals in hepatitis C virus (HCV) patients: A brief, updated report

Hepatitis C virus (HCV) is one of the leading causes of chronic liver disease affecting over 71 million people worldwide. An increased incidence of atherothrombotic events [e.g. coronary artery disease (CAD), atrial fibrillation (AF)] has been observed in HCV seropositive patients. On the other hand...

Descripción completa

Detalles Bibliográficos
Autores principales:	Canonico, Mario Enrico, Sanna, Giuseppe Damiano, Siciliano, Roberta, Scudiero, Fernando, Esposito, Giovanni, Parodi, Guido
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395984/ https://www.ncbi.nlm.nih.gov/pubmed/36016569 http://dx.doi.org/10.3389/fphar.2022.916361

Ejemplares similares

HIV/HCV Antiviral Drug Interactions in the Era of Direct-acting Antivirals
por: Rice, Donald P., et al.
Publicado: (2016)

Timing Strategies of Direct-Acting Antivirals and Biologics Administration in HCV-Infected Subjects with Inflammatory Bowel Diseases
por: Imperatore, Nicola, et al.
Publicado: (2017)

Emergence and Persistence of Resistance-Associated Substitutions in HCV GT3 Patients Failing Direct-Acting Antivirals
por: Mushtaq, Saima, et al.
Publicado: (2022)

Potential for Drug-Drug Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfected Patients
por: Poizot-Martin, Isabelle, et al.
Publicado: (2015)

Drug-induced thrombotic microangiopathy: An updated review of causative drugs, pathophysiology, and management
por: Mazzierli, Tommaso, et al.
Publicado: (2023)

Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs
por: Minosse, Claudia, et al.
Publicado: (2021)

IDX-184 is a superior HCV direct-acting antiviral drug: a QSAR study
por: Elfiky, Abdo A., et al.
Publicado: (2016)

Comparison of the Efficacies of Direct-Acting Antiviral Treatment for HCV Infection in People Who Inject Drugs and Non-Drug Users
por: Hsu, Jui-Ting, et al.
Publicado: (2022)

Sulfur-Containing Monoterpenoids as Potential Antithrombotic Drugs: Research in the Molecular Mechanism of Coagulation Activity Using Pinanyl Sulfoxide as an Example
por: Nikitina, Liliya E., et al.
Publicado: (2018)

Newer antithrombotic drugs
por: Sikka, Pranav, et al.
Publicado: (2010)

Risk of adverse outcomes following treatment with direct acting antiviral drugs in HCV infected patients with liver cirrhosis
por: Riaz, Hafiza Arooba, et al.
Publicado: (2023)

Strategy, Progress, and Challenges of Drug Repurposing for Efficient Antiviral Discovery
por: Li, Xinlei, et al.
Publicado: (2021)

Direct-Acting Antiviral Agents for HCV-Associated Glomerular Disease and the Current Evidence
por: Fabrizi, Fabrizio, et al.
Publicado: (2019)

Editorial: Brief research reports in experimental pharmacology and drug discovery: 2022
por: Hassan, Tahsin, et al.
Publicado: (2023)

Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update
por: Roguljic, Hrvoje, et al.
Publicado: (2021)

Editorial: Antiviral drugs and vaccines against important human respiratory viruses
por: Yang, Minghui, et al.
Publicado: (2022)

Are Interferon-Free Direct-Acting Antivirals for the Treatment of HCV Enough to Control the Epidemic among People Who Inject Drugs?
por: Lima, Viviane D., et al.
Publicado: (2015)

A new paradigm shift in antithrombotic therapy
por: Pudusseri, Anita, et al.
Publicado: (2013)

Antithrombotic Potential of Tormentil Extract in Animal Models
por: Marcinczyk, Natalia, et al.
Publicado: (2017)

HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents
por: Angeletti, Andrea, et al.
Publicado: (2019)

The ‘Viennese epidemic’ of acute HCV in the era of direct‐acting antivirals
por: Chromy, David, et al.
Publicado: (2022)

Dry Needling and Antithrombotic Drugs
por: Muñoz, María, et al.
Publicado: (2022)

How to use COVID-19 antiviral drugs in patients with chronic kidney disease
por: Kale, Ajinath, et al.
Publicado: (2023)

Drug-drug interactions with direct-acting antivirals — less is more
por: Wong, Grace Lai-Hung
Publicado: (2021)

Transplantation of HCV Viremic Livers into HCV Viremic Recipients Followed by Direct-acting Antiviral Therapy
por: Kapila, Nikhil, et al.
Publicado: (2019)

An Update on in Vivo Imaging of Extracellular Vesicles as Drug Delivery Vehicles
por: Gangadaran, Prakash, et al.
Publicado: (2018)

Chronic Drug-Induced Liver Injury: Updates and Future Challenges
por: Wang, Qiaoling, et al.
Publicado: (2021)

HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral Therapy
por: Chayama, Kazuaki, et al.
Publicado: (2015)

Directly Acting Antiviral-Based Treatment for HCV-Infected Persons Who Inject Drugs: A Multicenter Real-Life Study
por: Messina, Vincenzo, et al.
Publicado: (2020)

P1096: TREATMENT OF HEPATITIS C-ASSOCIATED MARGINAL ZONE LYMPHOMA(HCV+LMZ) WITH DIRECT-ACTING ANTIVIRAL DRUGS (DAAS)
por: Lepkov, Sergey, et al.
Publicado: (2023)

Editorial: Emerging and old viral diseases: Antiviral drug discovery from medicinal plants
por: Rahmatullah, Mohammed, et al.
Publicado: (2022)

European Drug Users at Risk from Illicit Fentanyls Mix
por: Pichini, Simona, et al.
Publicado: (2017)

Survival of HIV/HCV co-infected patients before introduction of HCV direct acting antivirals (DAA)
por: Dold, L., et al.
Publicado: (2019)

HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients
por: Brochado-Kith, Óscar, et al.
Publicado: (2021)

Antiplatelet and Antithrombotic Activity of a Traditional Medicine, Hwangryunhaedok-Tang
por: Kim, Kyungho, et al.
Publicado: (2019)

Drug–Drug Interactions Between Direct-Acting Antivirals and Psychoactive Medications
por: Smolders, E. J., et al.
Publicado: (2016)

Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era
por: Stevenson, Heather L., et al.
Publicado: (2016)

Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation
por: Martin, Natasha K., et al.
Publicado: (2016)

Role of Pharmacogenetics in Adverse Drug Reactions: An Update towards Personalized Medicine
por: Micaglio, Emanuele, et al.
Publicado: (2021)

Recent Information on Pan-Genotypic Direct-Acting Antiviral Agents for HCV in Chronic Kidney Disease
por: Fabrizi, Fabrizio, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ult21dit5qgiv2smie08hrghuh